Inhibition of PRMT5 in MTAP-deficient cancers offers a promising strategy to exploit this synthetic lethality, potentially improving outcomes in tumors harboring this common genomic alteration (115, 116, 117). This evidence concerns the gene PRMT5 and cancer.